SPECIAL NOTICE
B -- Use of Back-Scattering Inferometry Technology for the Development of Sexually Transmitted Infections Diagnostic Test
- Notice Date
- 3/4/2009
- Notice Type
- Special Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 200-2009-Q-11173
- Point of Contact
- Deborah T Workman,, Phone: 404-639-8893
- E-Mail Address
-
atl7@cdc.gov
- Small Business Set-Aside
- N/A
- Description
- NOTICE OF INTENT TO SOLE SOURCE: The Centers for Disease Control and Prevention (CDC) announces its intention to negotiate a sole source award with the Vanderbilt University Department of Chemistry, Nashville, TN to utilize Back-Scattering Interferometry (BSI) in developing new assays that will focus on detecting the presence of sexually transmitted disease (STD) antigens, including point-of-care test that potentially offer an alternative to traditional non-treponemal test (VDRL,RPR) and treponemal test (TP-PA, EIAs, FTA-Abs) and detect specific IgM antibody for the diagnosis of congenital syphilis. Currently, syphilis diagnosis is most commonly performed by serological tests, which are categorized into two groups: treponemal and non-treponemal tests. These tests have a variety of limitations, including that some of them can only be performed on serum and require quantities greater than 10 microliters. New technologies are being developed that can be adapted to sexually transmitted disease diagnosis, utilizing a reduced sample quantity as well as expanding the tests to whole blood, thereby mainstreaming the laboratory procedure by eliminating the requirement of venous blood collection. These technologies can be adapted to detect specific antigens and also organism-specific nucleic acid sequences by use of specific non-labeled probes. (BSI) is an advanced optical technique which allows for highly sensitive qualitative and quantitative, label-free detection of molecular interactions in free-solution or on-surface supports. BSI is a new technology which significantly accelerates assay development because it demonstrates zeptomole sensitivity, uses very small sample volumes (< 2 microliters), and requires little apriori knowledge of the molecular interactors. Specifically, the contractor shall perform the following tasks on this project: 1. Develop an assay to detect unlabeled human antibodies against treponemal protein antigens (example: 15-, 17-, 44, and or 47 kDa lipoproteins). All assays should involve label-free antigens and antibodies and require less than 10 ul of sample. The assay should be quick, less than 1 minute, and have sensitivity on the picomole level or better. 2. Develop an assay to detect unlabeled human antibodies against non-protein treponemal antigens, i.e. cardiolipin. 3. Analyze 100 characterized patient sera and distinguish reactive or positive human serum from normal human serum in order to distinguish active cases of syphilis. 4. Analyze the above patient sera for reactive IgM antibodies and reactive IgG antibodies. 5. In consultation with CDC, write a manuscript and submit for scientific publication. Vendor must have the capacity, resources, infrastructure and hands-on experience to develop and perform research experiments specifically using back-scattering interferometry technology. This technology is not commercially available and therefore the vendor is required to have full-developmental access (instrumentation and equipment necessary for the development of these new tests in-house or easily accessible with experienced staff available) to this technology in order to fulfill the requirements of this procurement. Vendor must have at least two years of expertise in back-scattering interferometry technology development. CDC intends to negotiate this requirement with Vanderbilt University under the authority of FAR 6.302-1 and HHSAR 306.302-1, Only One Responsible Source, and 41 U.S.C. 253(c)(1). This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses should be received by the March 25, 2009, at 4 PM, Eastern Standard Time (EST). All responses must be in writing and can be sent via email to atl7@cdc.gov or fax to 770-488-8350. No phone calls will be accepted.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=72879b5ccb01c675350189d4e3821a3b&tab=core&_cview=1)
- Place of Performance
- Address: Vanderbilt University, VU Station B, Box 351822, Nashville, Tennessee, 37235, United States
- Zip Code: 37235
- Zip Code: 37235
- Record
- SN01761253-W 20090306/090304215425-72879b5ccb01c675350189d4e3821a3b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |